
    
      This is an open-label Phase 1/2 study to determine the recommended dose and assess the
      safety, tolerability, pharmacokinetics (PK), immunogenicity, and efficacy of IMO-2125 when
      administered in combination with ipilimumab or pembrolizumab. The study will be conducted in
      2 parts; a dose-escalation portion (Phase 1) to evaluate safety and tolerability of multiple
      dose levels and a Phase 2 portion to assess efficacy.
    
  